ILLINGWORTH RESEARCH GROUP LIMITED

1. ILLINGWORTH RESEARCH GROUP LIMITED 2017-01-17 → present
2. ILLINGWORTH RESEARCH LIMITED 2011-04-01 → 2017-01-17
3. CLINICAL DEVELOPMENT AND SUPPORT SERVICES LIMITED 1998-10-26 → 2011-04-01

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Forvis Mazars LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors have prepared the financial statements on a going concern basis. The Company is in a net current asset and net asset position and the underlying trading of the Company will continue to be profitable going forward. Additionally, the Company has long-term relationships with a number of customers and suppliers across different geographic areas. The ultimate parent company Star Intermediate Holdings, Inc., has assured the directors of the provision of financial support if required, in the form of a letter of support for a period of at least 12 months from the approval of the accounts. The directors have also assessed that Star Intermediate Holdings, Inc. has sufficient funds to support the Company as required. Accordingly, the accompanying financial statements have been prepared on the assumption that the Company will continue as a going concern.”

Group structure

1. ILLINGWORTH RESEARCH GROUP LIMITED · parent
   1. Illingworth Research Group (Australia) PTY Ltd 100% · Australia · research for clinical trials
   2. Illingworth Research Group (Spain) Sociedad Limitada 100% · Spain · research for clinical trials
   3. Illingworth Research Group (France) SARL 100% · France · research for clinical trials
   4. Illingworth Research Group (Italy) S.R.L 100% · Italy · research for clinical trials

Significant events

• “During the year turnover and cost of sales decreased. These decreases are due to a slight reduction in the number of contracts being won. The business is now offering new service lines alongside its current offerings and as such although similar results are expected in 2025, it is anticipated that the company will see increased sales after this.”
• “Employee numbers have decreased to 101 (2023 129) following a period of aligning the business with the Syneos Health model and making effective use of the efficiencies of scale that brings.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -8.8%

  £30,434,222 → £27,741,265

• Cash

  -45.7%

  £2,361,675 → £1,281,469

• Net assets

  -39.3%

  £4,800,079 → £2,912,207

• Employees

  -21.7%

  129 → 101

• Operating profit

  -60%

  £2,338,790 → £935,177

• Profit before tax

  -59.4%

  £2,587,482 → £1,049,486

• Wages

  -11.4%

  £5,573,580 → £4,940,219

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers